Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women's health, announced today that its core product APL-1702 (trade ...

Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that its ...

Wisdom Bioscience, Inc., a biotechnology company pioneering non-invasive oral cancer diagnostics, today announced the formation of its Scientific Advisory Board (SAB) following the close of an initial ...

SAN FRANCISCO, May 22, 2025 /PRNewswire/ -- OncoSwab, a biotechnology company focused on early detection of cancer through non-invasive molecular testing, today announced it has entered into a ...

On Monday, members of the Lebanon City Fire Department were screen for esophageal cancer. It was conducted by Lucid Diagnostics, a company that develops innovative and non-invasive technologies to ...

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

A recent breakthrough study highlights how a simple at-home urine test could accurately detect prostate cancer. Researchers from Vanderbilt University and the University of Michigan suggest this ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the European Commission has ...

Study on optimizing serum-based lung cancer diagnosis using a multi-biomarker approach. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody ...